Log in to save to my catalogue

Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2315083321

Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

About this item

Full title

Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

Publisher

United States: Massachusetts Medical Society

Journal title

The New England journal of medicine, 2020-01, Vol.382 (2), p.130-139

Language

English

Formats

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a trial, patients who had undergone successful TAVR were assigned to rivaroxaban or antiplatelet therapy. In this substudy in patients who underwent CT, leaflet thickening and reduced leaflet motion at 90 days were less common with rivaroxaban. However, in the main trial, rivaroxaban was associated with a higher risk of death or thromboembolic c...

Alternative Titles

Full title

Reduced Leaflet Motion after Transcatheter Aortic-Valve Replacement

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2315083321

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2315083321

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa1911426

How to access this item